FT522
FT522-101
Phase 1 small_molecule completed
Quick answer
FT522 for Relapsed/Refractory B-Cell Lymphoma is a Phase 1 program (small_molecule) at FATE THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- FATE THERAPEUTICS INC
- Indication
- Relapsed/Refractory B-Cell Lymphoma
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed